Level 7 Staff Lounge

EMCR monthly morning tea - April

Date: Tuesday 18 April 2023
Time: 10:00am - 11:00am
Location: Level 7 Staff Lounge
Topic: Research translation at TRI and You – from basic research to clinical trials

Come along to the April EMCR morning tea to network as well as find out about how you can access the ‘translational’ at the Translational Research Institute. Whether you see yourself as a basic researcher or one keen to see their ideas turned into products, your medical research can have an impact outside your lab. And we want to help you make sure it does!  

At this morning tea, you’ll have the chance to meet the QUT and UQ/UniQuest technology transfer managers based at TRI as well as the Brandon Capital investment team. Their doors are always open to you to discuss your research and ways in which it could be commercialised and or investor-ready. 

You will also hear about the opportunities TRI offers through its Translation Pathways program for you to upskill and explore ways in which you can improve the translational outcomes from your research. 

What is Translational Research? It is a continuum from findings in basic research through to results that directly benefit humans. This can range from publishing papers to enhancing disease knowledge to improving patient treatment and care to informing policy. 

Bring your coffee mug and head up to the Staff lounge on level 7 to chat with other TRI-based early to mid-career researchers. Morning tea supplied.


Dr Tamsin Terry, Director, Commercialisation - Life Sciences, UniQuest
Tamsin is Commercialisation Director– Life Sciences at UniQuest with a particular focus in oncology, infectious disease and vaccines. Tamsin has an extensive background in Australian and UK research commercialisation and medtech industries encompassing small molecule drug and biologic development and medical device with additional experience in vaccine development and gene expression-based diagnostic assays/biomarkers. Prior to joining UniQuest in July 2018, Tamsin was R&D Director for the Wound Management Innovation CRC, responsible for directing research and development strategy across the CRC’s portfolio of innovative wound-focused research and had previous Research Director roles start-ups commercialising small molecule and antibody therapeutics and expression-based diagnostics.

Dr Andrew Leech, Director, Industry Engagement - Health, QUT 
Since completing a postdoctoral research fellowship in the USA and earning his qualifications as a patent and trademark attorney, Andrew has spent his career helping university academics to establish industry partnerships and commercialise their research. Having worked at institutions all up and down the east coast of Australia, he has a broad range of experience in different technical areas, but as the Director Industry Engagement – Health at QUT Andrew focuses on development and commercialisation of therapeutic and medical devices through licensing and spinout companies. Andrew has a PhD in Biochemistry from The University of Queensland and a Masters of Industrial Property law from the University of Technology Sydney.

Dr Goslik Schepers, Senior Investment Manager, Brandon Capital (Queensland)
Goslik has spent more than 20 years’ in the life sciences industry, with his experience spanning research, commercial, translation and investment roles. Goslik is passionate about research commercialisation, with demonstrated skills and experience in licensing, negotiation and deal-making. Prior to joining Brandon Capital Partners, Goslik was the GM of Business Development at QIMR Berghofer. He also worked as VP Business Development at the biopharmaceutical companies, Alchemia Ltd (AU-ASX) and Summit PLC (UK-AIM). Goslik has a Bachelor of Science from James Cook University, a Bachelor of Science (Honours) from The University of Melbourne and a PhD in Molecular and Development Biology from the University of Queensland. Goslik is a Graduate of the Australian Institute of Company Directors (AICD). Goslik is currently a director of Kimaritec and Sicario.

Dr Christina Kulis, Analyst, Brandon Capital (Queensland)
Prior to joining Brandon Capital in 2021, Christina was a research officer and project lead at The University of Queensland. Christina comes from extensive drug discovery and development experience. Working alongside Protagonist Therapeutics Pty Ltd (NASDAQ:PTGX), a global biotechnology company, Christina received unique insight into the impact of commercially driven research outcomes. In 2019, Christina completed an internship with Brandon Capital Partners and then throughout 2020 was involved in assisting a start-up life science company, Kimaritec Pty Ltd. Christina has a Bachelor of Biotechnology (Honours) and PhD in Medicinal Chemistry from The University of Queensland.